As part of negotiations, firm will purchase $10M of Dyax common stock.

Dyax  entered into an exclusive negotiation period with Dompé Farmaceutici for a European license to DX-88 in angioedema indications including hereditary angioedema (HAE), for which the company recently completed its second Phase III trial.

As a condition for the exclusive negotiation rights that end at the end of September, Dompé entered into a securities sale agreement with Dyax to purchase 2,008,032 million shares of Dyax common stock in a private placement at $4.98 per share, which represents a 57% premium over the closing price on July 10, 2008. The offering, which represents a total investment of $10 million, is expected to close on July 17, 2008.

“We look forward to finalizing a partnership with Dompé for DX-88 in angioedema indications, and believe that their regulatory and commercial capabilities in Europe could add significantly to the DX-88 franchise worldwide,” commented Henry E. Blair, chairman, president and CEO of Dyax. “Dompé’s premium, unconditional investment in Dyax highlights the value potential of the DX-88 franchise as well as our proprietary phage display discovery technology. This agreement, if finalized, will be another step toward the completion of our DX-88 global strategy, which also includes a partnership with Cubist Pharmaceuticals for surgical indications, and our own commercial infrastructure for hereditary angioedema within the U.S.”

Previous articleThe DNA Repair Company Licenses Discovery to Help with Development of Chemotherapy Theranostic
Next articleLonza and Kyowa Hakko Extend Strategic Collaboration